Cellectis Biotherapeutics - נכסים נקיים למניה בודדת CLLS

The price history of Cellectis S.A. (CLLS) reflects the dynamics of an asset currently valued at 0.41. The business leverages TALEN technology to develop off-the-shelf immunotherapeutic products. Cellectis S.A. (CLLS) adheres to ethical norms and environmental standards by reducing hazardous waste in its laboratories. Flawless operation of temperature-controlled aviation supply chains ensures the prompt global transportation of biomaterials.

Book value per share determines the portion of equity attributable to a single security, serving as a fundamental measure of an asset's intrinsic value relative to market quotes. By analyzing the historical book value chart for Cellectis S.A. (CLLS), an investor can assess the extent to which licensing revenues offset the binary risks of the oncology pipeline, ensuring capital stability and protection against bankruptcy.